SEC Comment Letter 0000000000-24-002914 to Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362) (LEXX)
Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362)
Date: March 18, 2024 · CIK: 0001348362 · Accession: 0000000000-24-002914
AI Filing Summary & Sentiment
File numbers found in text: 333-277863
Letter
United States securities and exchange commission logo March 15, 2024 Christopher Bunka Chairman and Chief Executive Officer Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, British Columbia VIX 2P7 Re:Lexaria Bioscience Corp. Registration Statement on Form S-1 Filed March 12, 2024 File No. 333-277863 Dear Christopher Bunka: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Avital Perlman
Show Raw Text
United States securities and exchange commission logo
March 15, 2024
Christopher Bunka
Chairman and Chief Executive Officer
Lexaria Bioscience Corp.
#100 – 740 McCurdy Road
Kelowna, British Columbia VIX 2P7
Re:Lexaria Bioscience Corp.
Registration Statement on Form S-1
Filed March 12, 2024
File No. 333-277863
Dear Christopher Bunka:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Avital Perlman